Innovent

信達生物製藥

INNOVENT BIOLOGICS, INC.

(Incorporated in the Cayman Islands with Limited Liability)

(Stock Code: 1801)

INSIDE INFORMATION ANNOUNCEMENT
UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE SECOND QUARTER OF 2025

This announcement is made by Innovent Biologics, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

In the first half of 2025, the Company achieved total product revenue exceeding RMB5.2 billion, reflecting a robust growth of over 35% year-on-year. In the second quarter, total product revenue was over RMB2.7 billion at year-on-year growth of over 30%. Driven by the growth of both oncology and general biomedicine product portfolios during this quarter: 1) oncology portfolio maintained good growth momentum, supported by sustained performance of major products and increasing contributions from new products; and 2) general biomedicine emerged as a new growth driver, with SINTBILO® (tafolecimab injection) and SYCUME® (Teprotumumab N01 injection) continuing their ramp-up through enhanced channel access and comprehensive marketing strategies. By the end of this quarter, the world's first glucagon/glucagon-like peptide-1 (GCG/GLP-1) dual receptor agonist, mazdutide, was approved by the National Medical Products Administration of China for weight management, adding a key medicine into our general biomedicine franchise.

The Company remains committed to its core strategies of sustainable growth and global innovation, with a solid pipeline across oncology and general biomedicine (which includes cardiovascular and metabolism, autoimmune, and ophthalmology). To date, the Company has 16 approved products, 2 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stages. The year 2025 is a pivotal year for the Company as it enters a new era of dual-engine growth and global innovation, moving steadily towards its vision of becoming a premier global biopharmaceutical company.

The financial information set out in this announcement was prepared based on internal management records of the Group which have not been audited or reviewed by external auditors, and as such, the data is for investors' information only. Such data may differ from figures to be disclosed in the audited or unaudited consolidated financial statements to be published by the Company (including but not limited to those published on an annual or semi-annual basis), due to various uncertainties during the process of collection and collating of such data. This announcement does not constitute, nor should it be construed as, an offer or solicitation for the purchase or sale of any securities or financial instruments of the Group.

By Order of the Board
Innovent Biologics, Inc.
Dr. De-Chao Michael Yu
Chairman and Executive Director

Hong Kong, China
August 7, 2025

As at the date of this announcement, the Board comprises Dr. De-Chao Michael Yu as Chairman and executive Director and Mr. Ronald Hao Xi Ede and Ms. Qian Zhang as executive Directors, and Dr. Charles Leland Cooney, Ms. Joyce I-Yin Hsu, Mr. Gary Zieziula, Dr. Shun Lu and Mr. Shuyun Chen as independent non-executive Directors.